Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Further Reading from MarketBeat.com Why 2 Small Biotechs May Hold the Key to New Cancer TreatmentsBy Nathan Reiff. Article Published: 3/12/2026. 
Key Points - Iovance and ImmunityBio each have a leading oncology product that has helped to massively boost sales and share prices in recent quarters.
- Despite major gains in recent trading, IOVA and IBRX shares still have at least 70% in upside potential going forward, according to analysts.
- Profitability remains a concern for both companies, even as sales of their top cancer drugs have surged.
- Special Report: Have $500? Invest in Elon's AI Masterplan
Cancer remains one of the greatest medical challenges for biotechnology firms, even as the oncology medicine market is expected to surge to $366 billion over the next eight years. Companies often take a niche approach, developing medicines that target specific cancer types with dedicated mechanisms. Fortunately, several promising treatments have shown significant potential—and with that comes the possibility of substantial sales. Two smaller biotech companies are seeing strong share price momentum thanks to their leading oncology medicines. Besides offering meaningful therapeutic potential, these drugs could help the firms move beyond penny-stock status and toward greater stability and eventual profitability. That said, both companies still face important risks, making them typical high-risk, high-reward biotech investments. Iovance's Powerful Cancer Drug Is Growing, But Production Challenges Are a Hurdle The Federal Reserve is selling banks their new FedNow system with one major promise: transfers will happen instantly, 24/7/365 with no more weekend or holiday delays—but when your money moves instantly through a centralized government hub, it can also be frozen instantly by automated algorithms inside the Fed's new network. Imagine it's 6:00 p.m. on a Friday when your account is instantly locked by a faceless government computer in Washington because an algorithm flagged a recent purchase or donation as suspicious, cutting you off from your own money until Monday morning or later with no way to pay for anything. Get the 4 steps to Fed-proof your savings now Iovance Biotherapeutics Inc. (NASDAQ: IOVA) bucked broader market trends in early March, surging nearly 37% during a week when the S&P 500 slipped about 1%. The rally added to a strong year-to-date performance that has more than doubled the stock so far. Still, with a consensus price target of $8.88, Wall Street expects more—that target implies roughly 71% upside from current levels. The main catalyst for Iovance is Amtagvi, a T-cell immunotherapy for certain types of melanoma. Amtagvi has been approved in the United States since 2024 and is gaining momentum both in sales and in the prospect of additional approvals in the E.U., U.K., and elsewhere. When administered with Proleukin, the company's IL-2 immunotherapy, management believes Amtagvi could exceed $1 billion in U.S. peak sales. Amtagvi's potential may extend beyond melanoma: the drug has received FDA Fast Track Designation for non-small cell lung cancer and could prove effective against other tumor types. Part of Iovance's outperformance this year followed its Q4 2025 earnings report in late February, when the company reported narrower-than-expected losses per share and $5 million in revenue. For the full year, revenue rose about 30% year over year. Iovance is a small-cap (about $2 billion) company and a penny stock, and despite the recent rally analysts remain cautious: roughly half of its roughly a dozen ratings are Hold or Sell. A particular concern is manufacturing. Because Amtagvi is a personalized therapy, it is costly and complex to produce, which could limit margins and delay profitability even as demand grows. Massive Sales Growth for ImmunityBio's Bladder Cancer Drug Although ImmunityBio Inc. (NASDAQ: IBRX) fell about 20% in March, its year-to-date performance dwarfs Iovance's: IBRX shares are up nearly 300% in 2026, and that may be just the beginning. Analysts' average price target of $13.60 implies roughly 70% more upside from current levels. ImmunityBio's leading product and primary growth driver is Anktiva, a therapy for certain types of bladder cancer. In February, shares jumped after the E.U. regulator granted conditional marketing authorization—one of a series of approvals the drug has received globally. Anktiva helped drive revenue to $113 million last year, roughly a 700% year-over-year increase. Like Amtagvi, Anktiva may have potential in other cancer indications, and ImmunityBio is actively exploring additional designations. Despite the dramatic run-up, IBRX remains speculative and risky. The company reported a net loss of $351 million for 2025 as research and development expenses remain high. Analysts appear somewhat more bullish on ImmunityBio than on Iovance: six of seven ratings cover the stock as a Buy or equivalent. | 
